Apixaban in subclinical atrial fibrillation: stroke-driven value amid economic uncertainty

Chung-Hsin Yeh^{1

2}, Shiuan-Chih Chen^{3

4

5}

Affiliations

¹ Department of Neurology, Yuan Rung Hospital, No. 201, Zhongzheng Road, Yuanlin, Changhua 510005, Taiwan.
² Department of Nursing, College of Nursing and Health, Da-Yeh University, No. 168, University Road, Dacun, Changhua 515006, Taiwan.
³ Department of Family and Community Medicine, Chung Shan Medical University Hospital, No. 110, Section 1, Jianguo North Road, Taichung 402306, Taiwan.
⁴ Department of Family and Community Medicine, Chung Shan Medical University Hospital Chung Shing Branch, No. 11, Section 2, Fuxing Road, Taichung 402020, Taiwan.
⁵ Institute of Medicine and School of Medicine, College of Medicine, Chung Shan Medical University, No. 110, Section 1, Jianguo North Road, Taichung 402306, Taiwan.

Editorial

Chung-Hsin Yeh et al. Europace. 2025.

. 2025 Oct 31;27(11):euaf262.

doi: 10.1093/europace/euaf262.

Chung-Hsin Yeh^{1

2}, Shiuan-Chih Chen^{3

4

5}

¹ Department of Neurology, Yuan Rung Hospital, No. 201, Zhongzheng Road, Yuanlin, Changhua 510005, Taiwan.
² Department of Nursing, College of Nursing and Health, Da-Yeh University, No. 168, University Road, Dacun, Changhua 515006, Taiwan.
³ Department of Family and Community Medicine, Chung Shan Medical University Hospital, No. 110, Section 1, Jianguo North Road, Taichung 402306, Taiwan.
⁴ Department of Family and Community Medicine, Chung Shan Medical University Hospital Chung Shing Branch, No. 11, Section 2, Fuxing Road, Taichung 402020, Taiwan.
⁵ Institute of Medicine and School of Medicine, College of Medicine, Chung Shan Medical University, No. 110, Section 1, Jianguo North Road, Taichung 402306, Taiwan.

No abstract available

Conflict of interest statement

Conflict of interest: none declared.

Cost-effectiveness of apixaban vs. aspirin for the reduction of thrombo-embolism in high-risk patients with device-detected atrial fibrillation: insights from the ARTESiA trial.
Lamy A, Sandhu RK, Tong W, McIntyre WF, Lopes RD, Granger CB, Wright DJ, Nielsen JC, Kutyifa V, Erath JW, Alings M, Birnie DH, Atar D, Hohnloser SH, Linde C, Kautzner J, Benezet-Mazuecos J, Camm AJ, Sticherling C, Gold MR, Larroudé CE, Healey JS. Lamy A, et al. Europace. 2025 Sep 1;27(9):euaf195. doi: 10.1093/europace/euaf195. Europace. 2025. PMID: 40886070 Free PMC article. Clinical Trial.

1. Lamy A, Sandhu RK, Tong W, McIntyre WF, Lopes RD, Granger CB et al. Cost-effectiveness of apixaban vs aspirin for the reduction of thrombo-embolism in high-risk patients with device-detected atrial fibrillation: insights from the ARTESiA trial. Europace 2025;27:euaf195. - PMC - PubMed
1. Lopes RD, Granger CB, Wojdyla DM, McIntyre WF, Alings M, Mani T et al. Apixaban vs aspirin according to CHA2DS2-VASc score in subclinical atrial fibrillation: insights from ARTESiA. J Am Coll Cardiol 2024;84:354–64. - PubMed
1. Shoamanesh A, Field TS, Coutts SB, Sharma M, Gladstone D, Hart RG et al. Apixaban versus aspirin for stroke prevention in people with subclinical atrial fibrillation and a history of stroke or transient ischaemic attack: subgroup analysis of the ARTESiA randomised controlled trial. Lancet Neurol 2025;24:140–51. - PubMed
1. Schnabel RB, Benezet-Mazuecos J, Becher N, McIntyre WF, Fierenz A, Lee SF et al. Anticoagulation in device-detected atrial fibrillation with or without vascular disease: a combined analysis of the NOAH-AFNET 6 and ARTESiA trials. Eur Heart J 2024;45:4902–16. - PMC - PubMed
1. McIntyre WF, Benz AP, Becher N, Healey JS, Granger CB, Rivard L et al. Direct oral anticoagulants for stroke prevention in patients with device-detected atrial fibrillation: a study-level meta-analysis of the NOAH-AFNET 6 and ARTESiA trials. Circulation 2024;149:981–8. - PubMed